Sonnet BioTherapeutics Forms Key Partnership to Tackle Diabetic Neuropathy
Sonnet BioTherapeutics Partners with Alkem for SON-080 Development
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) has made a significant move by entering a licensing agreement with Alkem Laboratories Limited. This strategic collaboration is focused on the development and commercialization of SON-080, which targets diabetic peripheral neuropathy (DPN) in India. As part of the agreement, Sonnet will receive $1.0 million upfront and potential milestone payments totaling another $1.0 million, plus royalties on net sales in the Indian market.
The Growing Need for Diabetic Neuropathy Treatment
The condition commonly known as DPN affects nearly half of diabetic patients, causing extreme pain and disability. Current available therapies majorly focus on pain relief, leaving a gap in treatment options for non-pain symptoms that stem from nerve damage. In India, the diabetic neuropathy market was estimated to be valued at approximately $120.3 million in 2023, with projections suggesting it could reach $246.7 million by 2030.
Sonnet's Innovative SON-080 Approach
SON-080 is a proprietary formulation of recombinant human Interleukin-6 (rhIL-6). The drug aims to stimulate peripheral nerve growth, thereby alleviating symptoms of DPN. Prior clinical trials have shown promising safety and efficacy results, indicating the potential to prevent and reverse neuropathy through low-dose administration.
Collaboration with Alkem Laboratories
Under this partnership, Alkem will be responsible for funding, developing, and promoting SON-080 for DPN, as well as for other neuropathies like Chemotherapy-Induced Neuropathy (CIPN) and Autonomic Neuropathy. Alkem's robust experience in the Indian pharmaceutical landscape positions them as a suitable partner for this venture. Sonnet will have the opportunity to leverage clinical data from Alkem's Phase 2 and Phase 3 trials in future collaborations in markets outside India.
Positive Clinical Results and Future Prospects
Recently, Sonnet shared data from its Phase 1b/2a clinical trial assessing SON-080 for CIPN, indicating the drug was well-tolerated with no harmful cytokine responses observed. Patient feedback highlighted rapid improvements in symptoms, showcasing the potential therapeutic benefits of SON-080. Sonnet is eager to expand this program and find additional partnership opportunities that could lead to a Phase 2 trial.
The Role of Leadership in this Partnership
Pankaj Mohan, CEO of Sonnet BioTherapeutics, expressed optimism about the collaboration, emphasizing Alkem’s expertise as vital for advancing SON-080 through clinical development. He underscored the significance of addressing the unmet medical needs of DPN patients globally.
About Alkem Laboratories Limited
Alkem Laboratories is a leading Indian pharmaceutical entity, recognized for its commitment to producing high-quality medications. With 50 years of experience, Alkem has established a diverse product portfolio that spans various therapy areas, including anti-infectives and neurology. Through its extensive facilities and R&D capabilities, Alkem is set to make a significant impact in the pharmaceutical domain.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an innovative biotechnology firm focused on developing targeted biologics, utilizing its proprietary FHAB technology. This advancement allows for refined delivery of therapeutic substances to combat cancer and other serious medical conditions. Sonnet is currently optimizing its lead program, SON-1010, targeting solid tumors and collaborating with Roche to enhance treatment outcomes.
Frequently Asked Questions
What is SON-080 developed for?
SON-080 is being developed to treat diabetic peripheral neuropathy (DPN) and other neurological disorders like chemotherapy-induced neuropathy.
What does the partnership with Alkem involve?
Alkem will fund, develop, and promote SON-080 in India, while Sonnet will receive upfront and milestone payments along with royalties from sales.
How large is the diabetic neuropathy market in India?
The market size for diabetic neuropathy in India is expected to grow from $120.3 million in 2023 to $246.7 million by 2030.
What is the significance of the clinical trial data for SON-080?
The clinical trial data for SON-080 indicates it is well-tolerated and has the potential to significantly alleviate symptoms of neuropathy, leading to improved patient outcomes.
What future plans does Sonnet have for SON-080?
Sonnet aims to expand SON-080’s program into Phase 2 trials and explore additional partnerships for further development opportunities.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Atlantic International Corp. Expands Growth Partnership in Food Sector
- Morguard Enhances Downtown Presence with Strategic Acquisition
- AI Image Generation Market Expected to Surge Beyond $1 Billion
- Discover the New Luxury Community at Crystal Lake by Toll Brothers
- ServiceNow and Zoom Collaborate to Enhance Productivity with AI
- Transformational Growth: How Autodesk Stock Has Thrived
- Cencora's Stock Growth: A Solid Investment Story Over 5 Years
- Affirm's Stock Sees Upgrade, Impactful Apple Pay Integration Ahead
- Revolutionizing Hearing Aids: Starkey Introduces Edge AI
- Joyful Holidays Await with CPKC's 2024 Train Tour Announcement
Recent Articles
- Compact EZBuck™ Regulator for Enhanced Intel Performance
- Exploring Warren Buffett's Key Investments in Top Companies
- TRIMEDX Expands Leadership Team to Drive Innovation Forward
- Insight Into Learning Technologies Group Plc's Market Position
- Ryde Launches Educational Awards to Support Young Learners
- SIMPPLE Ltd. Expands Footprint with New Contracts in ANZ
- Navitas Semiconductor Expands GaNSafe Offerings for Next-Gen Power
- Hurricane Milton's Impact on Global Insurance Landscape
- Cloud ERP Market Growth Driven by AI and Enhanced Efficiency
- HARMAN’s Ready Vision QVUE Wins 2024 Award for Innovative HUD Tech
- Unveiling the Emerging Giants in AI Investments
- Intelligent Bio Solutions Teams with Spirit Group for Impactful Drug Testing
- ClearSign Technologies Strengthens Position with New Burner Order
- Dragos Public Sector: Securing Government’s OT Cyber Landscape
- Aprea Therapeutics Welcomes Dr. Philippe Pultar as Advisor
- Avenue Therapeutics to Join Virtual Summit for Healthcare Insights
- iCoreConnect Partners with Dental Society for Enhanced Solutions
- Bayer Advances Elinzanetant for Menopause Symptom Relief
- Banzai Unveils Plans to Boost Annual Income Potential by $13.5M
- NGE Secures $110 Million Financing for Central Railway Project
- Avenue Therapeutics Showcases Insights at Healthcare Summit
- Recognizing Innovation: NTT's APN Project Wins Prestigious Award
- Empowering Volunteers: Kind Souls Foundation's Innovative Training
- Banzai's Innovative Business Adjustments Aim for Growth and Savings
- MilliporeSigma Unveils Major Investment in Testing Facility
- Helen Of Troy Shares Rise After Strong Q2 Performance Summary
- Entourage Health Updates on Financial Position and Strategy
- Naveris Expands NavDx Test Coverage to Revolutionize Diagnostics
- How XR Technologies are Transforming Manufacturing Operations
- Chartwell Retirement Residences Reveals Upcoming Q3 Results
- Understanding the Disclosure Requirements for Balanced Commercial Property Trust
- Phoenix Capital Group Inspires Young Oil and Gas Talent
- NewsXPartners Corporation Honored with Prestigious Leadership Award
- Target Stocks Shine as Cramer Highlights Buying Opportunities
- Recent Share Transactions by Executive Management at Admiral Group
- Celebrating Innovation: The Inaugural Cobalt Awards by Jack Henry
- Informatica Announces Upcoming Q3 2024 Financial Results Call
- Boeing Faces Challenges Ahead as Strikes and Downgrade Approach
- Understanding Keywords Studios Plc Position Disclosure Insights
- TruckerCloud's Ascension to the InsurTech100: A Game Changer
- NanoVibronix Partners with Urology Firm for European Sales Growth
- UATP Partners with Floa for Enhanced Payment Solutions
- Innovative Technology to Disrupt Hurricane Formation Through Patents
- Momentus Inc. Chosen by NASA for Innovative Launch Services
- Inspira Technologies Unveils Game-Changing Disposable Kit for Healthcare
- Transforming Financial Security: Cybersmarts.ai's AI Solution
- o9 Delivers Impressive Growth with Advancements in AI Solutions
- Byrna Technologies Achieves Record Revenue Growth in Q3 2024
- NGE Secures $110 Million Financing for Key Rail Project
- Mexico's Inflation Trends Promote Central Bank Rate Decisions